Journal article
Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial
Nature communications, Vol.12(1), pp.1967-10
03/30/2021
DOI: 10.1038/s41467-021-22177-1
PMID: 33785743
Abstract
Type III interferons have been touted as promising therapeutics in outpatients with coronavirus disease 2019 (COVID-19). We conducted a randomized, single-blind, placebo-controlled trial (NCT04331899) in 120 outpatients with mild to moderate COVID-19 to determine whether a single, 180 mcg subcutaneous dose of Peginterferon Lambda-1a (Lambda) within 72 hours of diagnosis could shorten the duration of viral shedding (primary endpoint) or symptoms (secondary endpoint). In both the 60 patients receiving Lambda and 60 receiving placebo, the median time to cessation of viral shedding was 7 days (hazard ratio [HR] = 0.81; 95% confidence interval [CI] 0.56 to 1.19). Symptoms resolved in 8 and 9 days in Lambda and placebo, respectively, and symptom duration did not differ significantly between groups (HR 0.94; 95% CI 0.64 to 1.39). Both Lambda and placebo were well-tolerated, though liver transaminase elevations were more common in the Lambda vs. placebo arm (15/60 vs 5/60; p = 0.027). In this study, a single dose of subcutaneous Peginterferon Lambda-1a neither shortened the duration of SARS-CoV-2 viral shedding nor improved symptoms in outpatients with uncomplicated COVID-19.
Details
- Title: Subtitle
- Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial
- Creators
- Prasanna Jagannathan - Stanford MedicineJason R Andrews - Stanford MedicineHector Bonilla - Stanford MedicineHaley Hedlin - Stanford UniversityKaren B Jacobson - Stanford MedicineVidhya Balasubramanian - Stanford UniversityNatasha Purington - Stanford UniversitySavita Kamble - Stanford UniversityChristiaan R de Vries - Stanford MedicineOrlando Quintero - Stanford MedicineKent Feng - Stanford UniversityCatherine Ley - Stanford MedicineDean Winslow - Stanford MedicineJennifer Newberry - Stanford MedicineKarlie Edwards - Stanford MedicineColin Hislop - Stanford MedicineIngrid Choong - Stanford MedicineYvonne Maldonado - Eiger Biopharmaceuticals (United States)Jeffrey Glenn - Stanford MedicineAmi Bhatt - Stanford MedicineCatherine Blish - Stanford MedicineTaia Wang - Stanford UniversityChaitan Khosla - Stanford UniversityBenjamin A Pinsky - Stanford MedicineManisha Desai - Stanford UniversityJulie Parsonnet - Stanford MedicineUpinder Singh - Stanford University
- Resource Type
- Journal article
- Publication Details
- Nature communications, Vol.12(1), pp.1967-10
- DOI
- 10.1038/s41467-021-22177-1
- PMID
- 33785743
- NLM abbreviation
- Nat Commun
- ISSN
- 2041-1723
- eISSN
- 2041-1723
- Grant note
- UL1 TR003142 / NCATS NIH HHS K08 AI151089 / NIAID NIH HHS UL1 TR001085 / NCATS NIH HHS T32 AI052073 / NIAID NIH HHS U01 AI150741 / NIAID NIH HHS Anonymous Donors / SU | School of Medicine, Stanford University (Stanford School of Medicine, Stanford University) R25 AI147369 / NIAID NIH HHS U01 AI150741-01S1 / NIAID NIH HHS U19 AI057229 / NIAID NIH HHS
- Language
- English
- Date published
- 03/30/2021
- Academic Unit
- Internal Medicine
- Record Identifier
- 9985244556302771
Metrics
1 Record Views